Aspreva Will Not Pursue CellCept For Myasthenia Gravis After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Study of Roche drug fails to meet both primary and secondary endpoints, company says.
You may also be interested in...
Aspreva, Roche Will Not Advance CellCept For Lupus Nephritis
Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.
Aspreva, Roche Will Not Advance CellCept For Lupus Nephritis
Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.
Roche, Aspreva Evaluating Filing Options For CellCept In Lupus Following Phase III Failure
Preliminary data from the induction phase of the trial show the study did not meet its primary superiority endpoint.